NEWS RELEASE

29 May 2014

info@arGEN-X.com | www.arGEN-X.com

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

29 May 2014

Breda, The Netherlands / Ghent, Belgium – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA).

arGEN-X reported in December 2013 that this study met its translational development goals: all pre-specified biological activity measures (e.g. target saturation, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favorable safety profile and identified a dose that was advanced into a larger safety study in patients with a range of hematological and solid tumors. Patient recruitment into this expanded study began in January 2014 in Europe (ClinicalTrials.gov Identifier: NCT01813539) and top-line results are expected in 2015.

The results will be presented in a poster as follows:

Poster Session: Developmental Therapeutics - Immunotherapy

Abstract number: #3023

Poster title: A Phase 1, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematological malignancies.

Date/time: Monday 2 June, 1:15pm-4:15pm, Room S405

Monday 2 June, 4:45pm-6:00pm, Room S406

Presenter: Ahmad Awada, Principal Investigator, Institut Jules Bordet

Authors: A. Awada[1], C. Rolfo[2], S. Rottey[3], L. Ysebrant de Lendonck[1], W. Schroyens[2], F. Offner[3], K. Silence[4], T. Dreier[4], M. Moshir[4], H. de Haard[4], M. Peeters[2], D. Bron[1], A. Thibault[4], P. Aftimos[1].

[1]Institut Jules Bordet, Université Libre de Bruxelles, Belgium; [2]Universitair Ziekenhuis Antwerpen, Belgium; [3]Universitair Ziekenhuis Gent, Belgium; [4]arGEN-X BVBA, Belgium.

For further information, please contact:

Tim Van Hauwermeiren
Chief Executive Officer
+32 9 243 40 70

Alain Thibault
Chief Medical Officer

E info@arGEN-X.com

arGEN-X BVBA (R&D Center)
Technologiepark 30
9052 Zwijnaarde
Belgium

Mark Swallow
David Dible
Citigate Dewe Rogerson
+44 207 282 2949

arGEN-X@citigatedr.co.uk

Beth DelGiacco
Stern Investor Relations
+1 212 362 1200

beth@sternir.com

About ARGX-110

ARGX-110 is a first-in-class monoclonal antibody that potently blocks CD70-induced tumor proliferation and tumor escape from immune surveillance. In addition, the POTELLIGENT®-enhanced antibody-dependent cellular cytotoxicity (ADCC) of ARGX-110 enables selective destruction of CD70-positive tumor cells. CD70 is overexpressed in the majority of cancer patients tested to date. Expectations of a favourable therapeutic index stem from its virtual absence in healthy tissues.

About the ARGX-110 Study

The Phase 1 study (ClinicalTrials.gov Identifier: NCT01813539) consists of a dose-escalation phase followed by an adaptive safety study conducted in patients with advanced, refractory cancer. The patient enrichment strategy relies on individual tumor screening for CD70 utilizing a reproducible immunohistochemistry method. In addition to traditional clinical and PK/PD endpoints, biomarkers documenting the three modes of action of ARGX-110 are being evaluated. Patient enrolment is planned at approximately 90 CD70-positive patients with either hematological or solid tumors. The study is managed jointly by arGEN-X and a consortium of leading academic institutions in Belgium and France.

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies – NHance®, ABDEG™ and POTELLIGENT® – further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

www.arGEN-X.com

arGEN-X BV Willemstraat 5, 4811 AH Breda, The Netherlands **arGEN-X BVBA** Technologiepark 30, 9052 Zwijnaarde, Belgium